SShort S.32· Tech · 10 sources · Sep 23, 2026StoryBasecamp Research Raises $140M for AI TherapiesBasecamp Research announced a $140 million Series C funding, led by S32 with broad participation from tech and philanthropic investors, to train a new generation of EDEN models and advance its AI-designed therapeutics including in vivo cell therapies, while expanding pharmaceutical partnerships. Andy Conrad of Section 32 will join Basecamp’s board as the round underscored the round’s oversubscribed nature and investor confidence in AI-driven drug design.Tech· Sep 23, 2026+7+33ShareChris Dalton·Sep 23, 2026Top commentPartnering with pharma companies early on should help turn these AI designs into something that works in real clinical settings.00ReplyGenius replyShareWrite a comment…
